Incyte Corporation
HealthcareNASDAQ:INCY · NASDAQ Global Select
+$0.70 today
Vol 1.47M · Avg 1.54M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $3.5B |
| Short-term Investments | $554.7M |
| Receivables | $1.1B |
| Inventory | $115.6M |
| Other Current | $301.3M |
| Total Current Assets | $5.5B |
| PP&E (Net) | $746.8M |
| Goodwill | $133.0M |
| Intangible Assets | $110.2M |
| Long-term Investments | $54.6M |
| Tax Assets | $452.5M |
| Other Non-current | $318.0M |
| Total Non-current Assets | $1.8B |
| Total Assets | $7.3B |
Analysis
Selected assets total $7.3B for Latest. The largest visible component is Cash & Equivalents at $3.5B, about 47.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.1B +83.5% | $1.7B -47.5% | $3.2B +8.9% | $3.0B +43.5% | $2.1B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $482.8M +2.7% | $470.3M +6.2% | $442.7M +53.9% | $287.5M -1.1% | $290.8M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $1.0B +20.1% | $853.2M +14.7% | $743.6M +15.3% | $644.9M +4.6% | $616.3M | $533.8M | $399.4M | -$1.7B |
| Inventory | $101.1M +71.7% | $58.9M -6.5% | $63.0M +50.0% | $42.0M +50.5% | $27.9M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $317.8M +88.2% | $168.9M -7.6% | $182.8M +9.5% | $167.0M +32.3% | $126.3M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $5.0B +55.1% | $3.2B -30.3% | $4.6B +13.5% | $4.1B +31.2% | $3.1B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $758.4M -4.5% | $794.2M +2.2% | $777.0M +1.5% | $765.6M +1.9% | $751.5M | $1.2B | $1.5B | $687.8M |
| Goodwill | $133.0M -14.5% | $155.6M +0.0% | $155.6M +0.0% | $155.6M +0.0% | $155.6M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $117.1M +2.9% | $113.8M -7.9% | $123.5M -4.4% | $129.2M -14.3% | $150.8M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $48.0M +155.1% | $18.8M -90.0% | $187.7M +40.4% | $133.7M -39.6% | $221.3M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $515.3M -32.4% | $762.1M +20.6% | $631.9M +38.0% | $457.9M -2.1% | $467.5M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | -$48.0M -113.3% | $360.8M +38.3% | $260.9M +145.9% | $106.1M +55.9% | $68.1M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $1.5B -30.9% | $2.2B +3.2% | $2.1B +22.2% | $1.7B -3.7% | $1.8B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $7.0B +27.8% | $5.4B -19.7% | $6.8B +16.1% | $5.8B +18.4% | $4.9B | $13.3B | $11.9B | $10.6B |
| Account Payables | $209.9M +6.3% | $197.5M +80.2% | $109.6M -60.5% | $277.5M +61.3% | $172.1M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $10.2M | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $23.8M -43.8% | $42.3M +495.0% | $7.1M | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $1.1B +47.2% | $724.8M +33.0% | $545.0M +25.0% | $435.9M +32.8% | $328.3M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $1.5B -7.7% | $1.6B +32.4% | $1.2B +7.2% | $1.2B +35.4% | $854.3M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $14.5M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $12.9M | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $216.1M -32.7% | $321.3M -0.4% | $322.7M +13.8% | $283.7M +2.3% | $277.4M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $288.2M -18.8% | $354.8M +0.8% | $351.9M +12.1% | $313.8M +1.5% | $309.0M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $1.8B -9.7% | $2.0B +25.4% | $1.6B +8.3% | $1.5B +26.4% | $1.2B | $14.7B | $3.7B | $9.6B |
| Common Stock | $198.0K +2.6% | $193.0K -13.8% | $224.0K +0.4% | $223.0K +0.9% | $221.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $213.8M +119.9% | -$1.1B -768.9% | $160.4M +136.7% | -$437.2M +43.8% | -$777.9M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $25.5M +294.1% | -$13.1M -200.1% | $13.1M -13.0% | $15.1M +177.5% | -$19.5M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $5.2B +49.9% | $3.4B -33.6% | $5.2B +18.8% | $4.4B +15.9% | $3.8B | $9.1B | $7.7B | $3.3B |
| Total Debt | $69.4M +59.4% | $43.5M +13.7% | $38.3M -7.6% | $41.5M -7.5% | $44.8M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$3.0B -84.2% | -$1.6B +48.2% | -$3.2B -9.1% | -$2.9B -44.6% | -$2.0B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Biogen Inc.
NASDAQ:BIIB
$29.53B
Illumina, Inc.
NASDAQ:ILMN
$24.35B
Royalty Pharma plc
NASDAQ:RPRX
$23.60B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.23B
Waters Corporation
NYSE:WAT
$23.17B
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Genmab A/S
NASDAQ:GMAB
$15.40B
Tenet Healthcare Corporation
NYSE:THC
$15.04B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does INCY have?
Incyte Corporation (INCY) reported $3.10B in cash and equivalents in fiscal 2025.
How much debt does INCY carry?
Incyte Corporation (INCY) reported $69.43M of total debt, with net debt of -$3,028,389,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.